Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Dow Chemical Company’s ( DOW - Analyst Report ) wholly owned subsidiary Dow AgroSciences entered into a strategic agreement with The Royal Barenbrug Group for developing and commercializing advanced germplasm in forage seeds. The two companies have a common goal of achieving growth in forage grasses. The financial terms of the transaction remained undisclosed.
As per the agreement, Dow AgroSciences will be a minority shareholder in Barenbrug Holding B.V., which is a part of The Royal Barenbrug Group. Further, Dow’’s subsidiary will provide Barenbrug access to select hybrid Brachiaria germplasm. On the other hand, Barenbrug will build a new facility in Brazil, where cleaning, coating and packaging will be done to process hybrid Brachiaria along with producing other tropical grasses and legumes.
With the partnership, Dow AgroSciences will be able to expand its seed portfolio into forage grass seed. Meanwhile, it will help Barenbrug to access latest technologies and germplasm.
Michigan-based Dow is a leading chemical company, whose products are used across a broad spectrum of industries. The company posted earnings of 61 cents a share (excluding specific one-time items) in the first quarter of 2012, surpassing the Zacks Consensus Estimate of 59 cents. However, it was below the year-ago adjusted earnings of 82 cents.
Revenues dropped marginally year over year to $14,719 million, lagging behind the Zacks Consensus Estimate of $15,342 million. Double-digit growth across agricultural and feedstock/energy businesses were masked by declines in performance materials and performance plastics franchises during the quarter.
The Agricultural Sciences segment posted sales of $1.8 billion in the quarter, up 14% year over year. Moreover, volumes and price rose 12% and 2%, respectively. The gains were broad-based across products and geographic areas, driven by customer adoption of new products, healthy agricultural market fundamentals, and an early spring planting season in North America.
Dow faces stiff competition from EI DuPont de Nemours & Co. ( DD - Analyst Report ) . Currently, the stock retains a Zacks #3 Rank, indicating a short-term “Hold” rating. Moreover, we have a long-term “Neutral” recommendation on the company.
Read the full Analyst Report on DD
Read the full Analyst Report on DOW